

Accepted Manuscript

Title: Re-Vaccination Following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

Author: Meighan Palazzo, Gunjan L. Shah, Olivia Copelan, Kenneth Seier, Sean M. Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S. Korde, Nikoletta Lendvai, Alexander M. Lesokhin, Sham Mailankody, David J. Chung, Guenther Koehne, C. Ola Landgren, Heather Landau, Sergio A. Giralt, Miguel-Angel Perales


PII: S1083-8791(17)31825-6
DOI: <https://doi.org/10.1016/j.bbmt.2017.12.795>
Reference: YBBMT 54977

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 17-5-2017
Accepted date: 18-12-2017

Please cite this article as: Meighan Palazzo, Gunjan L. Shah, Olivia Copelan, Kenneth Seier, Sean M. Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S. Korde, Nikoletta Lendvai, Alexander M. Lesokhin, Sham Mailankody, David J. Chung, Guenther Koehne, C. Ola Landgren, Heather Landau, Sergio A. Giralt, Miguel-Angel Perales, Re-Vaccination Following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/10.1016/j.bbmt.2017.12.795>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Highlights:

1. Inactivated vaccines are safe on lenalidomide maintenance after auto transplant.
2. Response rates are similar to previously reported after transplant.
3. Additional study is needed for live vaccines in this setting.

Re-vaccination following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

Meighan Palazzo ANP-C^{1*}, Gunjan L. Shah MD MS^{1,2*}, Olivia Copelan BA^{1,3}, Kenneth Seier MS⁴, Sean M. Devlin PhD⁴, Molly Maloy MS¹, Sheila Kenny MSN ANP-BC¹, Hani Hassoun MD^{2,5}, Neha S. Korde MD^{2,5}, Nikoletta Lendvai MD PhD^{2,5}, Alexander M. Lesokhin MD^{2,5}, Sham Mailankody MD^{2,5}, David J. Chung MD^{1,2}, PhD, Guenther Koehne MD PhD^{1,2}, C. Ola Landgren MD PhD^{2,5}, Heather Landau MD^{1,2}, Sergio A. Giralt MD^{1,2}, and Miguel-Angel Perales MD^{1,2}

*Contributed equally to this work

¹ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

² Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA

³ Case Western Reserve University School of Medicine, Cleveland, OH, 44106USA

⁴ Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

⁵ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

Corresponding Author:

Gunjan L. Shah, MD MS

Download English Version:

<https://daneshyari.com/en/article/8430094>

Download Persian Version:

<https://daneshyari.com/article/8430094>

[Daneshyari.com](https://daneshyari.com)